| Followers | 14 |
| Posts | 1734 |
| Boards Moderated | 0 |
| Alias Born | 06/14/2018 |
Friday, December 20, 2024 11:51:06 PM
A bit off topic, but as I touched on it.
If anyone is interested, the 7 1/15/27 LEAPS are:
AI $55, IOVA $15, KTOS $35, RTX $160, QCOM $250, MRVL $150, MU $140.
For earnings call options, I track the charts months in advance as the call options buying prices go up and down, I normally buy 2 to 4 weeks before the earnings date, normally within 10% to 15% of it's consistent lows, buy a strike price that is about 5% to 10% above the stock price at the time I am buying the call option, at an expiration date that is 1 to 2 weeks after the earnings date, and normally sell them the day after earnings before any volatility crush sets in.
The only exception is: As many times the call prices 2 to 5 days before the earnings tend to be in the "run up" stage, IF after I buy, and still before the earnings date, the calls are up 100% or more, I will sell 1/2 to recoup my investment and keep the rest for free for earnings, IF up 200% or more, I will sell 1/3 of them, etc. Stick with companies that either have a tendency to surprise on the upside, or that you have a reasonable rational expectation that they will surprise to the upside.
Merry Christmas, do your own Due Diligence.
If anyone is interested, the 7 1/15/27 LEAPS are:
AI $55, IOVA $15, KTOS $35, RTX $160, QCOM $250, MRVL $150, MU $140.
For earnings call options, I track the charts months in advance as the call options buying prices go up and down, I normally buy 2 to 4 weeks before the earnings date, normally within 10% to 15% of it's consistent lows, buy a strike price that is about 5% to 10% above the stock price at the time I am buying the call option, at an expiration date that is 1 to 2 weeks after the earnings date, and normally sell them the day after earnings before any volatility crush sets in.
The only exception is: As many times the call prices 2 to 5 days before the earnings tend to be in the "run up" stage, IF after I buy, and still before the earnings date, the calls are up 100% or more, I will sell 1/2 to recoup my investment and keep the rest for free for earnings, IF up 200% or more, I will sell 1/3 of them, etc. Stick with companies that either have a tendency to surprise on the upside, or that you have a reasonable rational expectation that they will surprise to the upside.
Merry Christmas, do your own Due Diligence.
Recent MRKR News
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/20/2026 08:08:49 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/20/2026 08:07:05 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/20/2026 08:05:49 PM
- Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results • GlobeNewswire Inc. • 03/18/2026 09:31:30 PM
- Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference • GlobeNewswire Inc. • 02/18/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 09:06:45 PM
- Good Morning America Features Baylor College of Medicine Pancreatic Cancer Study Utilizing Marker Therapeutics’ MAR-T Cell Technology • GlobeNewswire Inc. • 01/26/2026 12:00:00 PM
- Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer • GlobeNewswire Inc. • 01/05/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/19/2025 09:10:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/19/2025 09:01:15 PM
- Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 11/17/2025 09:22:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 12:20:47 PM
- Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 11/14/2025 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2025 10:29:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/05/2025 12:36:59 PM
- Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors • GlobeNewswire Inc. • 11/05/2025 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/04/2025 10:09:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/04/2025 10:03:27 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 11/04/2025 09:54:39 PM
- Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting • GlobeNewswire Inc. • 11/03/2025 02:15:00 PM
- Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program • GlobeNewswire Inc. • 10/06/2025 11:30:59 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/06/2025 11:30:37 AM
- Marker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference • GlobeNewswire Inc. • 08/28/2025 12:00:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/26/2025 11:16:20 AM
